Imlunestrant vs Palazestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2028 · NCT07905001 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Palazestrant
Developed by Olema Pharmaceuticals, Inc.
NCT04505826 · Phase 1/2 · completed
The study was nonrandomized, unblinded, and single-arm, with participants receiving OP-1250 at sequential dose levels and no placebo or active comparator. Its results were descriptive rather than a formal comparative test: dose-limiting toxicities were 0/42 during dose escalation, while confirmed partial responses included 4/62 participants at 120 mg once daily; therefore, the primary outcomes were not formally met or missed against a control.
Next expected readout: December 2027 · NCT05508906 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Imlunestrant | Palazestrant |
|---|---|---|
| PFS, median | 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT049753087 other results
| —Trial running · NCT06016738 |
| OS, median | —Trial running · NCT04975308 | —Trial running · NCT06016738 |
| ORR | 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
| —Trial running · NCT06016738 |
| Clinical benefit rate | 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
| —Trial running · NCT06016738 |
PFS, median
- Imlunestrant
- 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT04975308
7 other results
- 5.5 vs 3.8 NCT04975308
- 9.4 NCT04975308
- 5.5 NCT04975308
- 9.2 vs 7.4 NCT04975308
- 7.4 vs 5.5 NCT04975308
- 14.5 NCT04975308
- 9.2 NCT04975308
- Palazestrant
- —Trial running · NCT06016738
OS, median
- Imlunestrant
- —Trial running · NCT04975308
- Palazestrant
- —Trial running · NCT06016738
ORR
- Imlunestrant
- 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 11.6% vs 5.9% NCT04975308
- 21.1% NCT04975308
- 9.4% NCT04975308
- Palazestrant
- —Trial running · NCT06016738
Clinical benefit rate
- Imlunestrant
- 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 46.4% vs 36.4% NCT04975308
- 62.9% NCT04975308
- 44.1% NCT04975308
- Palazestrant
- —Trial running · NCT06016738
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Imlunestrant: 4 of 4 rows · Palazestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Imlunestrant | Palazestrant |
|---|---|---|
| Dropout rate | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | —300 mg QDa NCT04505826 · Phase 1/2 show 14 more results0%300 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 0%210 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 0%150 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 0%120 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 0%90 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 0%60 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 0%30 mg QD NCT04505826 · Phase 1/2 |
| Discontinued due to AEs | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | —300 mg QDa NCT04505826 · Phase 1/2 show 14 more results—300 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 |
| Serious AEs | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 28.6%300 mg QDa NCT04505826 · Phase 1/2 show 14 more results—300 mg QD NCT04505826 · Phase 1/2 28.6%210 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 40%150 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 19.3%120 mg QD NCT04505826 · Phase 1/2 57.1%120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 33.3%90 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 12.1%60 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 0%30 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 |
| Most frequent reported AEs | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | show 7 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Imlunestrant
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Palazestrant
show 7 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Imlunestrant's landscape · Palazestrant's landscape